BONUS BIOGROUP LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.7 ILa | -0.60% |
|
-1.18% | 0.00% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 301.1 | 374.5 | 483.5 | 1,454 | 224.2 | 195 |
| Enterprise Value (EV) 1 | 292.4 | 380.2 | 472.6 | 1,387 | 182.6 | 180.2 |
| P/E ratio | -16.1 x | -16.8 x | -22 x | -16.1 x | -5.79 x | -6.84 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -16 x | -18.4 x | -24.6 x | -36.8 x | -5.13 x | -6.41 x |
| EV / FCF | -41.7 x | -74.5 x | -55.4 x | -50.4 x | -8.92 x | -10.4 x |
| FCF Yield | -2.4% | -1.34% | -1.8% | -1.98% | -11.2% | -9.58% |
| Price to Book | -94.8 x | -27.3 x | 15.8 x | 17.2 x | 3.98 x | 6.66 x |
| Nbr of stocks (in thousands) | 811,497 | 841,467 | 998,981 | 1,154,057 | 1,167,925 | 1,167,925 |
| Reference price 2 | 0.3710 | 0.4450 | 0.4840 | 1.260 | 0.1920 | 0.1670 |
| Announcement Date | 3/30/19 | 3/31/20 | 3/26/21 | 3/31/22 | 3/30/23 | 3/29/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -18.25 | -20.69 | -19.23 | -37.7 | -35.6 | -28.14 |
| EBIT 1 | -18.45 | -20.91 | -19.44 | -38.14 | -37.05 | -29.79 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -18.74 | -22.24 | -22.02 | -90.08 | -38.7 | -28.53 |
| Net income 1 | -18.74 | -22.24 | -22.02 | -90.08 | -38.7 | -28.53 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.0231 | -0.0264 | -0.0220 | -0.0781 | -0.0331 | -0.0244 |
| Free Cash Flow 1 | -7.017 | -5.104 | -8.528 | -27.53 | -20.47 | -17.26 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/30/19 | 3/31/20 | 3/26/21 | 3/31/22 | 3/30/23 | 3/29/24 |
1ILS in Million2ILS
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 5.77 | - | - | - | - |
| Net Cash position 1 | 8.64 | - | 10.9 | 67.2 | 41.7 | 14.8 |
| Leverage (Debt/EBITDA) | - | -0.279 x | - | - | - | - |
| Free Cash Flow 1 | -7.02 | -5.1 | -8.53 | -27.5 | -20.5 | -17.3 |
| ROE (net income / shareholders' equity) | 392% | 263% | -260% | -156% | -55% | -66.6% |
| ROA (Net income/ Total Assets) | -147% | -152% | -41.6% | -30.6% | -25.9% | -31.2% |
| Assets 1 | 12.78 | 14.59 | 52.94 | 294.3 | 149.5 | 91.55 |
| Book Value Per Share 2 | -0 | -0.0200 | 0.0300 | 0.0700 | 0.0500 | 0.0300 |
| Cash Flow per Share 2 | 0.0100 | 0 | 0.0200 | 0.0700 | 0.0500 | 0.0100 |
| Capex 1 | 0.34 | 0.19 | 0.25 | 5.81 | 6.39 | 0.82 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/30/19 | 3/31/20 | 3/26/21 | 3/31/22 | 3/30/23 | 3/29/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 52.22M | |
| -28.62% | 924M | |
| -19.49% | 130M | |
| -6.57% | 68.37M | |
| +5.69% | 60.11M |
- Stock Market
- Equities
- BONS Stock
- Financials Bonus BioGroup Ltd.
